Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

25 trials 11 recruiting Commercial sponsor

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

11 Recruiting

12 Completed trials

5 Countries active

45 Unique IMPs

100% Results reported

Phase II

Phase III: 2 Phase II/III: 2 Phase II: 18 Phase I/II: 1 Phase I (Other): 2

Oversight events:

3 temporary halts across 2 trials

View oversight register →

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastrooesophageal cancer 4 Non-small cell lung cancer 2 HER2 positive gastric cancer 2 Hepatocellular carcinoma 1 Non-small cell lung cancer stage IIIA 1 B-cell lymphoma 1 Diffuse large B-cell lymphoma recurrent 1 Hepatic cancer 1 Non-small cell lung cancer stage III 1 Cholangiocarcinoma 1 Oesophageal adenocarcinoma 1 Biliary tract operation 1

Top IMPs

FLUOROURACIL 6 CALCIUM FOLINATE PENTAHYDRATE 5 OXALIPLATIN 5 DURVALUMAB 4 DOCETAXEL 3 ATEZOLIZUMAB 2 BEVACIZUMAB 2 CEMIPLIMAB 2 GLOFITAMAB 2 OBINUTUZUMAB 2 PEMBROLIZUMAB 2 TISLELIZUMAB 2

All trials — page 2

25 total

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 Phase III 3 countries CALCIUM FOLINATE; CALCIUM FOLINATE PENTAHYDRATE; FLUOROURACIL; FOLINIC ACID; IRI…

Showing 25–25 of 25 trials

← All sponsors A–Z